Expression of apoptosis regulating proteins identifies stage II and III colon cancer patients with high risk of recurrence

Background and Objectives Deregulation of apoptosis related genes may be associated with poor outcome in cancer. Aim of the present study was to investigate the prognostic role of expression levels of apoptosis related proteins in stage II and III colon cancer. Methods From tumor samples of 386 stag...

Full description

Saved in:
Bibliographic Details
Published inJournal of surgical oncology Vol. 109; no. 3; pp. 255 - 265
Main Authors Belt, Eric J.Th, Stockmann, Hein B.A.C., Delis-van Diemen, Pien M., Bril, Herman, Tijssen, Marianne, van Essen, Hendrik F., Heymans, Martijn W., Beliën, Jeroen A.M., Carvalho, Beatriz, Cillessen, Saskia A.G.M., Meijer, Gerrit A.
Format Journal Article
LanguageEnglish
Published United States Blackwell Publishing Ltd 01.03.2014
Wiley Subscription Services, Inc
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Background and Objectives Deregulation of apoptosis related genes may be associated with poor outcome in cancer. Aim of the present study was to investigate the prognostic role of expression levels of apoptosis related proteins in stage II and III colon cancer. Methods From tumor samples of 386 stage II and III colon cancer patients, DNA was isolated and tissue microarrays were constructed. Expression of Bcl‐2, Bcl‐X, BAX, XIAP, Fas, FasL and c‐FLIP was evaluated and PCR‐based microsatellite instability analysis was performed. Results High FasL expressing tumors were associated with high disease recurrence rates in stage II colon cancer patients overall, as was low Bcl‐X expression in microsatellite stable stage II patients. In stage II patients, a multivariable model based on FasL and Bcl‐XL expression revealed a significant association with disease free survival (DFS). In stage III colon cancer patients, low Bcl‐2, low BAX and low Fas expression levels were associated with worse outcome. In these patients a multivariable model based on angioinvasion and Bcl‐2, Fas and FasL expression was significantly associated with DFS. Conclusions Stage II patients with low Bcl‐X and high FasL protein expression levels and stage III patients with low Fas, high FasL and low Bcl‐2 expression could be considered as high risk for disease recurrence. J. Surg. Oncol. 2014 109:255–265. © 2013 Wiley Periodicals, Inc.
Bibliography:ark:/67375/WNG-DNGDFVR0-0
ArticleID:JSO23495
istex:E4D6B1A927E6EB15A6737496349DC9C676B21FD6
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0022-4790
1096-9098
DOI:10.1002/jso.23495